In the BioHarmony Drug Report Database

"Preview" Icon

Ibalizumab

Trogarzo (ibalizumab) is an antibody pharmaceutical. Ibalizumab was first approved as Trogarzo on 2018-03-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against T-cell surface glycoprotein CD4.

 

Trade Name

 

Trogarzo
 

Common Name

 

ibalizumab
 

ChEMBL ID

 

CHEMBL1743029
 

Indication

 

hiv infections
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Ibalizumab structure rendering